News

Article

FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain

Key Takeaways

  • Urcosimod has received FDA fast track designation for neuropathic corneal pain, enabling expedited regulatory processes and frequent FDA interactions.
  • Neuropathic corneal pain involves severe pain due to nerve damage and inflammation, with no current FDA-approved treatments available.
SHOW MORE

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor

(Image Credit: AdobeStock/Prostock-studio)

(Image Credit: AdobeStock/Prostock-studio)

The US Food and Drug Administration (FDA) has granted fast track designation to OKYO Pharma for urcosimod for the treatment of neuropathic corneal pain (NCP).1

NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head, and the exact cause is unknown but is thought to result from nerve damage to the cornea combined with inflammation. There is currently no FDA-approved drug to treat NCP.

OKYO had previously applied for fast track designation in March of this year.2 Fast track designation allows for the company to have more frequent meetings with the FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval, as well as the use of a rolling FDA review to expedite its regulatory path.

Gary S. Jacob, PhD, CEO of OKYO Pharma, commented on the FDA’s decision in a press release from the company.

“We are thrilled with the FDA’s Fast Track designation for urcosimod in the treatment of neuropathic corneal pain. This milestone underscores our commitment to advancing innovative therapies that can make a meaningful difference in patients’ lives. We look forward to working closely with the FDA to bring this promising treatment to patients as quickly as possible,” said Jacob.

The company describes urcosimod as a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion.

Recently, the company announced positive data on the long-term stability of urcosimod for the treatment of neuropathic corneal pain (NCP).3 The company noted that it has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is currently in a phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients, which had the first patient dosed in October 2024.

References:
  1. FDA grants OKYO Pharma fast track designation to urcosimod for neuropathic corneal pain. Published May 1, 2025. Accessed May 1, 2025. https://okyopharma.com/fda-grants-okyo-pharma-fast-track-designation-to-urcosimod-for-neuropathic-corneal-pain/
  2. Harp M. OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain. Ophthalmology Times. Published March 10, 2025. Accessed May 1, 2025. https://www.ophthalmologytimes.com/view/okyo-pharma-files-application-for-fast-track-designation-with-the-fda-for-urcosimod-for-the-treatment-of-neuropathic-corneal-pain
  3. Harp M. OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain. Ophthalmology Times. Published March 31, 2025. Accessed May 1, 2025. https://www.ophthalmologytimes.com/view/okyo-pharma-releases-positive-long-term-stability-data-for-urcosimod-in-neuropathic-corneal-pain

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.